萘-1-基乙酰氯 | 5121-00-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 萘-1-基乙酰氯
• 中文别名: 1-萘基乙酰氯；2-（1-萘）乙醇氯；2-(1-萘基)乙醇酰氯；2-(1-萘)乙醇氯
• 英文名称: naphthalen-1-yl-acetyl chloride
• 英文别名: 1-naphthylacetyl chloride；2-(naphthalen-1-yl)acetyl chloride；naphthylacetyl chloride；1-naphthyl-acetic acid chloride；1-naphthaleneacetyl chloride；2-(1-Naphthyl)Ethanoyl Chloride；2-naphthalen-1-ylacetyl chloride
• CAS: 5121-00-6
• 化学式: C₁₂H₉ClO
• mdl: MFCD00175852
• 分子量: 204.656
• InChiKey: DSVAZLXLRDXHKO-UHFFFAOYSA-N

物化性质

• 熔点：
  137-139 °C(Solv: ligroine (8032-32-4); dichloromethane (75-09-2))
• 沸点：
  130℃/0.6mm
• 密度：
  1.23
• 稳定性/保质期：

  在常温常压下保持稳定

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  8
• 安全说明：
  S26,S36,S37,S39
• 危险类别码：
  R34
• 包装等级：
  II
• 危险品运输编号：
  UN 3265
• 储存条件：
  常温、避光、存放在阴凉干燥处并密封保存。

SDS

Name:	2-(1-Naphthyl)ethanoyl chloride 97% Material Safety Data Sheet
Synonym:	2-(1-Naphtyl)acetyl chlorid
CAS:	5121-00-6

Section 1 - Chemical Product MSDS Name:2-(1-Naphthyl)ethanoyl chloride 97% Material Safety Data Sheet
Synonym:2-(1-Naphtyl)acetyl chlorid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
5121-00-6	2-(1-Naphthyl)ethanoyl chloride	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5121-00-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Viscous liquid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 130 deg C @0.6mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H9ClO
Molecular Weight: 205

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, alcohols.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5121-00-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(1-Naphthyl)ethanoyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3265
Packing Group: III
IMO
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 5121-00-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 5121-00-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5121-00-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  萘-1-基乙酰氯 在 aluminum (III) chloride 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以58%的产率得到1-苊酮
  参考文献：
  名称：

  Ylidenemalononitrile Enamines 作为伯胺的荧光“开启”指示剂

  摘要：

  Ylidenemalononitrile enamines 进行快速胺交换，然后与伯胺环化产生荧光产物，其发射强度高达起始材料的 900 倍。通过 X 射线晶体学识别荧光物质后，我们证明胺交换的速率取决于底物，并且通过简单的结构变化可以在整个可见光谱范围内调整荧光。我们进一步证明了它们在生物分子标记中的潜在应用。

  DOI：

  10.1021/ja509058u
• 作为产物：
  描述：

  1-萘乙酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 8.0h， 以93%的产率得到萘-1-基乙酰氯
  参考文献：
  名称：

  A new ortho-phenylenediamine-based cleft for selective sensing of H2PO4− and ATP

  摘要：

  以正苯二胺为基础的化学传感器1已被设计和合成。该化学传感器1在CH3CN中选择性结合H2PO4−，由于悬挂的萘基单元之间的π–π堆积，显示出456 nm的激发态二聚体发射。传感器1还能够在pH = 6.5的CH3CN–H2O（1 : 1, v/v）中荧光分辨ATP与ADP和AMP。

  DOI：

  10.1039/c1nj20116f
• 作为试剂：
  描述：

  1-萘乙酸 、 草酰氯 、 氮 在 N,N-二甲基甲酰胺 萘-1-基乙酰氯 、 二氯甲烷 作用下， 以 二氯甲烷 为溶剂， 反应 12.33h， 以to give 1-naphthylacetylchloride 21.90 g (99%) as a dark oil的产率得到萘-1-基乙酰氯
  参考文献：
  名称：

  Arylsulfonamide ethers, and methods of use thereof

  摘要：

  本发明涉及新型芳基磺酰胺醚化合物及其制药组合物。本发明还描述了将新型芳基磺酰胺醚化合物及其制药组合物用作白细胞介素-1β转化酶和ICE家族中其他半胱氨酸蛋白酶的抑制剂。此外，本发明还描述了使用本发明的化合物或其制药组合物治疗卒中、炎症性疾病、脓毒症休克、再灌注损伤、阿尔茨海默病和志贺氏菌病的方法。

  公开号：

  US20030096826A1

文献信息

• Directed Remote Lateral Metalation: Highly Substituted 2-Naphthols and BINOLs by In Situ Generation of a Directing Group
  作者：Jignesh J. Patel、Marju Laars、Wei Gan、Johnathan Board、Matthew O. Kitching、Victor Snieckus

  DOI：10.1002/anie.201805203

  日期：2018.7.20

  general synthesis of highly substituted 2‐naphthols based on a new carbanionic reaction sequence is demonstrated. The reaction exploits the dual nature of lithium bases consisting of consecutive ring opening of readily available coumarins with either LiNEt2 or LiNiPr2 into Z‐cinnamamides, thus generating a directing group in situ and allowing, by conformational freedom, a lateral directed remote metalation

  演示了基于新的碳负离子反应序列的高度取代的2-萘酚的一般合成。该反应利用了锂碱的双重性质，即将容易获得的具有LiNEt 2或LiN i Pr 2的香豆素连续开环成Z肉桂酰胺，从而在原位生成一个导向基团，并通过构象自由度允许横向定向的远程金属化以进行闭环反应，得到芳基2-萘酚，收率好至极好。可以将这些转换组合起来，以提供更有效的单锅法。对远端横向金属化步骤的机械洞察力，证明了对Z的要求描述了肉桂酰胺。还报道了该方法在高度取代的3,3'-二芳基BINOL配体合成中的应用。
• Biochemical, Structural, and Biological Evaluation of Tranylcypromine Derivatives as Inhibitors of Histone Demethylases LSD1 and LSD2
  作者：Claudia Binda、Sergio Valente、Mauro Romanenghi、Simona Pilotto、Roberto Cirilli、Aristotele Karytinos、Giuseppe Ciossani、Oronza A. Botrugno、Federico Forneris、Maria Tardugno、Dale E. Edmondson、Saverio Minucci、Andrea Mattevi、Antonello Mai

  DOI：10.1021/ja101557k

  日期：2010.5.19

  demethylase inhibitors. This drug is a clinically validated antidepressant known to target monoamine oxidases A and B. These two flavoenzymes are structurally related to LSD1 and LSD2. Mechanistic and crystallographic studies of tranylcypromine inhibition reveal a lack of selectivity and differing covalent modifications of the FAD cofactor depending on the enantiomeric form. These findings are pharmacologically

  LSD1 和 LSD2 组蛋白去甲基化酶涉及许多生理和病理过程，从肿瘤发生到疱疹病毒感染。这里介绍了一项全面的结构、生化和细胞研究，以探索这些酶在表观遗传疗法中的潜力。这种方法使用反苯环丙胺作为设计新型去甲基酶抑制剂的化学支架。这种药物是一种经过临床验证的抗抑郁药，已知靶向单胺氧化酶 A 和 B。这两种黄素酶在结构上与 LSD1 和 LSD2 相关。反苯环丙胺抑制的机理和晶体学研究表明，根据对映体形式，FAD 辅因子缺乏选择性和不同的共价修饰。这些发现在药理学上是相关的，因为反苯环丙胺目前作为外消旋混合物给药。合成了大量反苯环丙胺类似物并筛选了抑制活性。我们发现 LSD 和 MAO 酶的共同进化起源，尽管它们的功能和底物特异性无关，但反映在相关的配体结合特性上。鉴定了一些具有部分酶选择性的化合物。这些新抑制剂之一的生物活性是用选择的急性早幼粒细胞白血病细胞模型评估的，因为其发病机制包括几种
• Transamidation for the Synthesis of Primary Amides at Room Temperature
  作者：Jiajia Chen、Yuanzhi Xia、Sunwoo Lee

  DOI：10.1021/acs.orglett.0c00958

  日期：2020.5.1

  Various primary amides have been synthesized using the transamidation of various tertiary amides under metal-free and mild reaction conditions. When (NH4)2CO3 reacts with a tertiary amide bearing an N-electron-withdrawing substituent, such as sulfonyl and diacyl, in DMSO at 25 °C, the desired primary amide product is formed in good yield with good funcctional group tolerance. In addition, N-tosylated

  在无金属和温和的反应条件下，使用各种叔酰胺进行转酰胺作用，可以合成出各种伯酰胺。当（NH4）2CO3在25°C的DMSO中与带有N吸电子取代基的叔酰胺（如磺酰基和二酰基）反应时，可以形成具有良好官能团耐受性的高收率的所需伯酰胺产物。另外，N-甲苯磺酸化的内酰胺衍生物通过开环反应提供了它们相应的N-甲苯磺酰胺基烷基酰胺产物。
• [EN] 1, 3, 9-TRIAZASPIRO[5.5] UNDECAN-2-ONE COMPOUNDS<br/>[FR] COMPOSÉS DE LA 1,3,9-TRIAZASPIRO[5.5]UNDÉCAN-2-ONE
  申请人：BAYER AG

  公开号：WO2020048827A1

  公开（公告）日：2020-03-12

  The present invention covers 1,3,9-triazaspiro[5.5]undecan-2-one compounds of general formula (I) and general formula (I-a): (I) and (I-a), in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

  本发明涵盖了一般式(I)和一般式(I-a)的1,3,9-三氮杂螺[5.5]十一烷-2-酮化合物：(I)和(I-a)，其中R1、R2、R3和R4如本文所定义，制备所述化合物的方法，用于制备所述化合物的中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗和/或预防疾病的药物组合物，特别是治疗过度增殖性疾病，作为唯一药剂或与其他活性成分组合使用。
• Development of [¹⁸F]Maleimide-Based Glycogen Synthase Kinase-3β Ligands for Positron Emission Tomography Imaging
  作者：Kongzhen Hu、Debasis Patnaik、Thomas Lee Collier、Katarzyna N. Lee、Han Gao、Matthew R. Swoyer、Benjamin H. Rotstein、Hema S. Krishnan、Steven H. Liang、Jin Wang、Zhiqiang Yan、Jacob M. Hooker、Neil Vasdev、Stephen J. Haggarty、Ming-Yu Ngai

  DOI：10.1021/acsmedchemlett.6b00405

  日期：2017.3.9

  radiotracers for positron emission tomography (PET) imaging is of paramount importance, because such a noninvasive imaging technique would allow better understanding of the link between the activity of GSK-3β and central nervous system disorders in living organisms, and it would enable early detection of the enzyme's aberrant activity. Herein, we report the synthesis and biological evaluation of a series

  糖原合酶激酶3β（GSK-3β）的失调与神经退行性和精神病性疾病的发病机制有关。因此，开发用于正电子发射断层摄影（PET）成像的GSK-3β放射性示踪剂至关重要，因为这种无创成像技术可以更好地了解GSK-3β活性与活生物体中枢神经系统疾病之间的联系，从而可以及早发现该酶的异常活性。在此，我们报告了一系列高亲和力GSK-3β抑制剂氟取代的马来酰亚胺衍生物的合成和生物学评估。实现了潜在的GSK-3β示踪剂[18F] 10a的放射性合成。在啮齿动物中进行的体内PET初步成像研究显示，大脑摄取中等，尽管在大脑中未观察到饱和结合。有必要进一步完善铅支架，以开发用于中枢神经系统PET成像的[18F]标记的GSK-3放射性示踪剂。